The cGMP Pathway and Inherited Photoreceptor Degeneration: Targets, Compounds, and Biomarkers

Genes (Basel). 2019 Jun 14;10(6):453. doi: 10.3390/genes10060453.

Abstract

Photoreceptor physiology and pathophysiology is intricately linked to guanosine-3',5'-cyclic monophosphate (cGMP)-signaling. Here, we discuss the importance of cGMP-signaling for the pathogenesis of hereditary retinal degeneration. Excessive accumulation of cGMP in photoreceptors is a common denominator in cell death caused by a variety of different gene mutations. The cGMP-dependent cell death pathway may be targeted for the treatment of inherited photoreceptor degeneration, using specifically designed and formulated inhibitory cGMP analogues. Moreover, cGMP-signaling and its down-stream targets may be exploited for the development of novel biomarkers that could facilitate monitoring of disease progression and reveal the response to treatment in future clinical trials. We then briefly present the importance of appropriate formulations for delivery to the retina, both for drug and biomarker applications. Finally, the review touches on important aspects of future clinical translation, highlighting the need for interdisciplinary cooperation of researchers from a diverse range of fields.

Keywords: apoptosis; cyclic GMP; drug delivery systems; necrosis; retina; translational medicine.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cell Death / genetics
  • Cyclic GMP / genetics
  • Cyclic GMP / metabolism*
  • Cyclic Nucleotide-Gated Cation Channels / genetics
  • Humans
  • Photoreceptor Cells / metabolism*
  • Photoreceptor Cells / pathology
  • Retina / metabolism*
  • Retina / pathology
  • Retinal Degeneration / genetics*
  • Retinal Degeneration / metabolism
  • Retinal Degeneration / physiopathology
  • Signal Transduction / genetics

Substances

  • Cyclic Nucleotide-Gated Cation Channels
  • Cyclic GMP